Paige, a digital pathology diagnostics company, has received De Novo marketing authorization from the Food and Drug Administration for its artificial intelligence software that helps detect prostate cancer.
The Paige Prostate software analyzes digitized biopsy slides and identifies areas that could be cancerous for the pathologist to review further.
“The approval is a landmark achievement in the...
